I understand the frustration but try to keep things in perspective:
1. Per TRIBLive article, additional TPIV Phase 2 trials for TPIV vaccines prior to movint to Phase 3
I believe he said "May require" not "Will require"
2. AZN drug trial set-back and uncertainty, AZN share price down under $30 yesterday
You are putting way to much weight in AZN... they are just one of many fish in a big pond and as I've commented before their latest setback was for small cell lung cancer not ovarian..
3. Phase I long term study is not statistically significant, question on patient population not resolved.
You have no numbers or mathematical justification for this...
4. No MAYO paper to date, why it is the middle of AUG, result were to be "published soon"???
That is up to MAYO not TPIV management.
5. Potential risk of MAYO trials going forward without above compelling Phase I long term paper
How is this relevant? The trials have already started and will continue regardless of long term paper...
6. Another round of disappointing and dilutive financing
I am still unclear why they needed this latest round as cash was heavy so I do agree with you here.
7. Upon further investigation, there is a closer relationship to Iroquios than I was aware of at the time and TPIV used others mentioned in the article for services. Also, there has always been "talk" of investors manipulating stock price, lower TPIV share price resulted in significant reduction in strike price for warrants right before developments planned to be announced??? Did large investors dump shares to suppress share price and then have strike prices for warrants reduced, it appears so? Why aren't large investors like Dart upset, Wilson terminated, maybe it is because investors like Dart can cover initial investment and buy or add to position cheaper, not bad deal, lets keep Wilson.
I agree with some of these statements but we have known for some time all the big players. It appears they could not get price movement up in the stock to have he warrants executed at higher prices so this was the only real option.
8. Disappointing TPIV200 trial amendment announced this week making it more inclusive and correcting population for statistical significance. This will increase cost and schedule.
That is fair but in the end this is a smart move.
9. Continued executive turnover, (was Bonfiglio a bad hire, there was plenty of time to assess him while he was consulting for TPIV). Also. continued poor overall performance by Wilson led to #1 - #9.
We don't know why he left....
10. No action by TPIV BOD to respond to poor performance of TPIV management like Wilson.
No comment.
It is too late for existing management team to turn this around, no remaining credibility and cash evaporating, unfortunately share price goes down until someone hits a home run, way too much risk for new investors, people need to reduce positions and hope to average down, where, who know but much closer to cash position of $0.50 to $1.00. Remember who gort you to this point and do something about it. GLTA.
Report TOS
